文献速递肝胆胰外科胃肠外科

双阶段肝切除与单阶段肝切除联合对侧切除或消融治疗晚期双侧结直肠癌肝转移的比较

Two-Stage Hepatectomy vs One-Stage Major Hepatectomy with Contralateral Resection or Ablation for Advanced Bilobar Colorectal Liver Metastases.
PubMed 文献 · J Am Coll Surg · 2018-02-14

本研究回顾性分析1998至2015年间227例接受右半肝或扩大右半肝切除并处理I、II和/或III段同步结直肠癌肝转移的患者,比较双阶段肝切除(TSH)与单阶段肝切除(OSH)联合对侧切除或射频消融(RFA)的术后结局和总生存(OS)。结果显示TSH组术后主要并发症和肝功能不全发生率更低,5年OS率更高。

要点

  • TSH与较低的术后主要并发症(14% vs 26%)和肝功能不全(6% vs 20%)相关。
  • TSH组5年OS率高于OSH组(35% vs 24%)。
  • 完成两阶段TSH的患者5年OS率高于OSH无RFA(50% vs 20%)和OSH有RFA(50% vs 24%)。

核心结论

  • 对于晚期双侧结直肠癌肝转移患者,TSH与较少的并发症相关,且在意向治疗分析和按治疗分析中均与更好的OS相关。

研究设计与样本

  • 回顾性队列研究,纳入1998至2015年间227例接受右半肝或扩大右半肝切除并处理I、II和/或III段同步结直肠癌肝转移的患者。

主要发现

  • 227例患者中,126例(56%)至少接受TSH第一阶段,101例(44%)接受OSH(29例(13%)无RFA,72例(32%)有RFA)。
  • TSH组术后主要并发症发生率为14%,OSH组为26%(p=0.03)。
  • TSH组术后肝功能不全发生率为6%,OSH组为20%(p=0.001)。
  • TSH组5年OS率为35%,OSH组为24%(p=0.016)。
  • 完成两阶段TSH的患者5年OS率为50%,OSH无RFA组为20%(p=0.023),OSH有RFA组为24%(p<0.0001)。

临床怎么用

  • 对于需右半肝切除的晚期双侧结直肠癌肝转移,可考虑TSH以降低术后主要并发症和肝功能不全风险。
  • TSH可能改善总生存,完成两阶段治疗者生存获益更明显。

局限性

  • 回顾性研究设计,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both 2-stage hepatectomy (TSH) and 1-stage hepatectomy (OSH) represent feasible strategies for resection of advanced bilobar colorectal liver metastases (CLM). However, the influence of the surgical approach on postoperative outcomes and overall survival (OS) is unknown. To define the optimal surgical approach for advanced bilobar CLM requiring right hemihepatectomy, we compared short-term and long-term outcomes after TSH and OSH with contralateral resection or radiofrequency ablation (RFA). STUDY DESIGN: We retrospectively reviewed 227 patients with bilobar CLM, who underwent right or extended right hepatectomy with treatment of synchronous CLM in segments I, II, and/or III, between 1998 and 2015. Postoperative outcomes and OS were compared between patients who underwent TSH and those who underwent OSH. RESULTS: Of the 227 patients, 126 (56%) underwent at least the first stage of TSH, and 101 (44%) underwent OSH, 29 (13%) without RFA and 72 (32%) with RFA. Two-stage hepatectomy was associated with a lower incidence of postoperative major complications (14% vs 26%, p = 0.03) and postoperative hepatic insufficiency (6% vs 20%, p = 0.001) than OSH. The 5-year OS rate was higher for patients assigned to TSH than for those who underwent OSH (35% vs 24%, p = 0.016). Patients who completed both stages of TSH had a higher 5-year OS rate than patients who underwent OSH without RFA (50% vs 20%, p = 0.023) or OSH with RFA (50% vs 24%, p < 0.0001). CONCLUSIONS: In patients with advanced bilobar CLM, TSH is associated with fewer complications than OSH. Both TSH in intention-to-treat analysis and completed TSH in as-treated analysis were associated with better OS than OSH.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Mizuno T, Cloyd JM, Omichi K, et al. Two-Stage Hepatectomy vs One-Stage Major Hepatectomy with Contralateral Resection or Ablation for Advanced Bilobar Colorectal Liver Metastases. J Am Coll Surg. 2018. PMID: 29454099. doi:10.1016/j.jamcollsurg.2018.01.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。